529 related articles for article (PubMed ID: 25832504)
1. Sox2 antagonizes the Hippo pathway to maintain stemness in cancer cells.
Basu-Roy U; Bayin NS; Rattanakorn K; Han E; Placantonakis DG; Mansukhani A; Basilico C
Nat Commun; 2015 Apr; 6():6411. PubMed ID: 25832504
[TBL] [Abstract][Full Text] [Related]
2. WWC1 and NF2 Prevent the Development of Intrahepatic Cholangiocarcinoma by Regulating YAP/TAZ Activity through LATS in Mice.
Park J; Kim JS; Nahm JH; Kim SK; Lee DH; Lim DS
Mol Cells; 2020 May; 43(5):491-499. PubMed ID: 32451369
[TBL] [Abstract][Full Text] [Related]
3. Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis.
Tanaka K; Osada H; Murakami-Tonami Y; Horio Y; Hida T; Sekido Y
Cancer Lett; 2017 Jan; 385():215-224. PubMed ID: 27773750
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of miR-130b enhances stem cell-like phenotype in glioblastoma by inactivating the Hippo signaling pathway.
Zhu G; Wang Y; Mijiti M; Wang Z; Wu PF; Jiafu D
Biochem Biophys Res Commun; 2015 Sep; 465(2):194-9. PubMed ID: 26241672
[TBL] [Abstract][Full Text] [Related]
5. KIBRA exhibits MST-independent functional regulation of the Hippo signaling pathway in mammals.
Moleirinho S; Chang N; Sims AH; Tilston-Lünel AM; Angus L; Steele A; Boswell V; Barnett SC; Ormandy C; Faratian D; Gunn-Moore FJ; Reynolds PA
Oncogene; 2013 Apr; 32(14):1821-30. PubMed ID: 22614006
[TBL] [Abstract][Full Text] [Related]
6. The Hippo pathway member Nf2 is required for inner cell mass specification.
Cockburn K; Biechele S; Garner J; Rossant J
Curr Biol; 2013 Jul; 23(13):1195-201. PubMed ID: 23791728
[TBL] [Abstract][Full Text] [Related]
7. Myeloid Zinc Finger 1 and GA Binding Protein Co-Operate with Sox2 in Regulating the Expression of Yes-Associated Protein 1 in Cancer Cells.
Verma NK; Gadi A; Maurizi G; Roy UB; Mansukhani A; Basilico C
Stem Cells; 2017 Dec; 35(12):2340-2350. PubMed ID: 28905448
[TBL] [Abstract][Full Text] [Related]
8. The Hippo pathway regulator KIBRA promotes podocyte injury by inhibiting YAP signaling and disrupting actin cytoskeletal dynamics.
Meliambro K; Wong JS; Ray J; Calizo RC; Towne S; Cole B; El Salem F; Gordon RE; Kaufman L; He JC; Azeloglu EU; Campbell KN
J Biol Chem; 2017 Dec; 292(51):21137-21148. PubMed ID: 28982981
[TBL] [Abstract][Full Text] [Related]
9. Hippo/YAP signaling pathway is involved in osteosarcoma chemoresistance.
Wang DY; Wu YN; Huang JQ; Wang W; Xu M; Jia JP; Han G; Mao BB; Bi WZ
Chin J Cancer; 2016 May; 35():47. PubMed ID: 27206784
[TBL] [Abstract][Full Text] [Related]
10. SOX2 antagonizes WWC1 to drive YAP1 activation in esophageal squamous cell carcinoma.
Chai Y; Li Q; Zhao H; Zhang Z; Yu X; Pang L; Liu Z; Zhao J; Wang L; Li F
Cancer Med; 2019 Nov; 8(16):7055-7064. PubMed ID: 31560173
[TBL] [Abstract][Full Text] [Related]
11. PPARγ agonists promote differentiation of cancer stem cells by restraining YAP transcriptional activity.
Basu-Roy U; Han E; Rattanakorn K; Gadi A; Verma N; Maurizi G; Gunaratne PH; Coarfa C; Kennedy OD; Garabedian MJ; Basilico C; Mansukhani A
Oncotarget; 2016 Sep; 7(38):60954-60970. PubMed ID: 27528232
[TBL] [Abstract][Full Text] [Related]
12. SOX2 maintains the stemness of retinoblastoma stem-like cells through Hippo/YAP signaling pathway.
Zhao N; Zhou L; Lu Q; Wang S; Sun Y; Ding Y; Liu M; He H; Lang T
Exp Eye Res; 2022 Jan; 214():108887. PubMed ID: 34890603
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Exposure to Imatinib Mesylate Downregulates Hippo Pathway and Activates YAP in a Model of Chronic Myelogenous Leukemia.
Chorzalska A; Kim JF; Roder K; Tepper A; Ahsan N; Rao RSP; Olszewski AJ; Yu X; Terentyev D; Morgan J; Treaba DO; Zhao TC; Liang O; Gruppuso PA; Dubielecka PM
Stem Cells Dev; 2017 May; 26(9):656-677. PubMed ID: 28103766
[TBL] [Abstract][Full Text] [Related]
14. Merlin/NF2-Lin28B-let-7 Is a Tumor-Suppressive Pathway that Is Cell-Density Dependent and Hippo Independent.
Hikasa H; Sekido Y; Suzuki A
Cell Rep; 2016 Mar; 14(12):2950-61. PubMed ID: 26997273
[TBL] [Abstract][Full Text] [Related]
15. Sox2 is required for tumor development and cancer cell proliferation in osteosarcoma.
Maurizi G; Verma N; Gadi A; Mansukhani A; Basilico C
Oncogene; 2018 Aug; 37(33):4626-4632. PubMed ID: 29743593
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional co-repressor function of the hippo pathway transducers YAP and TAZ.
Kim M; Kim T; Johnson RL; Lim DS
Cell Rep; 2015 Apr; 11(2):270-82. PubMed ID: 25843714
[TBL] [Abstract][Full Text] [Related]
17. Regulation of YAP by mechanical strain through Jnk and Hippo signaling.
Codelia VA; Sun G; Irvine KD
Curr Biol; 2014 Sep; 24(17):2012-7. PubMed ID: 25127217
[TBL] [Abstract][Full Text] [Related]
18. PAR1 participates in the ability of multidrug resistance and tumorigenesis by controlling Hippo-YAP pathway.
Fujimoto D; Ueda Y; Hirono Y; Goi T; Yamaguchi A
Oncotarget; 2015 Oct; 6(33):34788-99. PubMed ID: 26431277
[TBL] [Abstract][Full Text] [Related]
19. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.
Janse van Rensburg HJ; Azad T; Ling M; Hao Y; Snetsinger B; Khanal P; Minassian LM; Graham CH; Rauh MJ; Yang X
Cancer Res; 2018 Mar; 78(6):1457-1470. PubMed ID: 29339539
[TBL] [Abstract][Full Text] [Related]
20. Elevated expression of Par3 promotes prostate cancer metastasis by forming a Par3/aPKC/KIBRA complex and inactivating the hippo pathway.
Zhou PJ; Xue W; Peng J; Wang Y; Wei L; Yang Z; Zhu HH; Fang YX; Gao WQ
J Exp Clin Cancer Res; 2017 Oct; 36(1):139. PubMed ID: 29017577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
